(Reuters) – The U.S. Food and Drug Administration could authorize COVID-19 boosters from Pfizer Inc and BioNTech SE for use in 16- and 17-year olds as soon as next week, the Wall Street Journal reported late on Monday, citing a person familiar with the planning.
(Reporting by Akriti Sharma in Bengaluru; Editing by Rashmi Aich)